

---

# Contents

## General Part

CHAPTER 1	
<b>Definition of the Sentinel Lymph Node and Basic Principles of Detection . .</b>	<b>3</b>
References . . . . .	4
CHAPTER 2	
<b>Main Techniques of Sentinel Lymph Node Labeling . . . . .</b>	<b>5</b>
Good Practice for Radiation Protection in the Operating Room . . . . .	5
Radioactivity Monitoring . . . . .	7
Good Radiation Protection Practice in the Pathology Laboratory . . . . .	8
References . . . . .	8
CHAPTER 3	
<b>Different Aspects Dependent on Type and Localization of the Primary . . . .</b>	<b>11</b>
Male Cancers . . . . .	16
Female Cancers . . . . .	17
References . . . . .	19
CHAPTER 4	
<b>Basic Strategies in Sentinel Node Detection and Exclusion or Verification of Cancer Metastasis into the Regional Node(s) . . . . .</b>	<b>23</b>
Early Developments and Continuous Improvements . . . . .	23
Possible Prescreening Methods for SLN Detection and Evaluation . . . . .	24
Tracers Most Frequently Used for Detection of SLN . . . . .	25
Critical Points of the SLN Detection Process . . . . .	27
References . . . . .	27
CHAPTER 5	
<b>Positron Emission Tomography: Significance for Preoperative N-Staging . . .</b>	<b>31</b>
Introduction . . . . .	31
Imaging Principles . . . . .	31

Radiopharmacy . . . . .	32
Quantitative Measurements . . . . .	33
Clinical Applications . . . . .	34
Patient Preparation . . . . .	34
Diagnosis of Primary Tumors . . . . .	34
Diagnosis of Lymph Node Metastases . . . . .	35
Staging of Disease . . . . .	35
Monitoring Effects of Therapy . . . . .	35
Limitations of PET Imaging . . . . .	35
Exclusion of Brain Metastases in Staging Programs . . . . .	36
System-immanent Properties of PET to Support the Sentinel Node Concept . . . . .	36
References . . . . .	36

## CHAPTER 6

<b>Detection and Radiological Imaging of SLN . . . . .</b>	<b>39</b>
Methodical Work-up and Improvements . . . . .	40
Techniques in Sentinel Node Detection . . . . .	43
Intraoperative Sentinel Node Detection by Use of the Gamma Probe . . . . .	43
Efforts at Optimization in <sup>99m</sup> Nanocolloid-Mediated Sentinel Node Localization . . . . .	44
Histo- and Cytopathological Diagnosis . . . . .	44
MAGE-A3 Marker Function in Breast Cancer Patients Sentinel Node Evaluation . . . . .	46
Retrospective Evaluation of the Significance of SLN Located Mediastinally or Along the Mammaria Interna by Radioimaging . . . . .	46
Inclusion and Exclusion Criteria for Sentinel Node Investigation . . . . .	47
Criteria for Clinical and Histopathological Sentinel Node Evaluation (Breast Cancer) . . . . .	48
Comparative Experimental Tracer Studies . . . . .	49
References . . . . .	49

## CHAPTER 7

<b>Lymphatic Drainage to the SLN . . . . .</b>	<b>51</b>
Time Schedule . . . . .	51
Involvement of the Regional Lymph Nodes in Breast Cancer . . . . .	52
Direct and Secondary Hematogenous Metastasis of Breast Cancer . . . . .	54
Is Intraoperative SLN Staging Possible in Breast Cancer Cases? . . . . .	55
References . . . . .	57

## CHAPTER 8

<b>Specific Developments in Sentinel Node Labeling Using <sup>99m</sup>Tc-Colloids . . . . .</b>	<b>59</b>
Introduction . . . . .	59
Radionuclides in Conventional and Routine Nuclear Medicine Applications . . . . .	59

Quality of the Colloids Used and the Particle Size .....	60
Injection Techniques Using <sup>99m</sup> Tc Nanocolloids and/or Blue Dyes in Breast Cancer Cases .....	62
Precision in Tracer Administration .....	64
Danger of Opening of Capillaries and Venules with Increasing Risk of Hematogenous Cancer Cell Transport .....	65
Use of Liposomes for Radioimaging Within the Sentinel Node Concept	65
References .....	69

CHAPTER 9

<b>Experience with and Suggestions for Cancer of Different Types and in Different Sites</b> .....	71
Breast Cancer .....	71
Malignant Melanomas .....	76
Cancers of the Head and Neck and of the Upper Aerodigestive Tract ..	80
Lung Cancer .....	81
Gastric and Neuroendocrine Cancers .....	82
Colorectal Cancers .....	83
Urogenital Cancers .....	85
References .....	86

CHAPTER 10

<b>General Techniques in Surgical Investigations</b> .....	89
Initial Remarks on the Histopathology of the Lymphatic System .....	89
Significance of Labeling of the Different Cellular Compartments of the Lymph Nodes for Radiological Diagnosis .....	89
Critical Points in Blue Dye (Patent Blue) Mapping .....	90
Timing in Blue Staining Methods .....	91
Probe Guidance in Surgical Treatment .....	91
Practical Use and Servicing of the Gamma Probe .....	91
Good Practice in Combined Use of Dye and <sup>99m</sup> Tc-labeling Procedures	92
Determination of the SLN's Location and Procedure for Its Excision ..	92
Pitfalls of SLN Labeling and Detection .....	94
SLN Investigation by Pathologists in Cooperation with Cytopathologists .....	94
Handling of Histopathological Procedures .....	95
Benefits of Sentinel Node Evaluation Over Primary Axillary Revision ..	96
Use of Radiodiagnostic Techniques .....	96
Choice of the Labeled Contrast Solution .....	96
Plans for Improvements to the Quality of the Contrast Media .....	99
References .....	99

CHAPTER 11

<b>Radiation-Detecting Systems</b> .....	101
Introduction and Steps in Development .....	101
Preconditions for Detector Quality .....	102

Development of the Modern Gamma Camera Systems . . . . .	103
Set-up and Function of the Gamma Camera . . . . .	104
Operation of a Digital Gamma Camera System . . . . .	105
Quality Requirements for Optimal Function of Commercially Available Gamma Probes . . . . .	105
New Developments in Gamma Camera Devices . . . . .	106
Operation-oriented Requirements for the Detection of the SLNs . . . . .	106
Optimizing Gamma Ray Measurement . . . . .	108
Important Factors in Performance of the Detector . . . . .	109
Quality Criteria for Gamma Probes and Dosimetric Consequences . . . . .	110
Management of Electromedical Safety . . . . .	110
References . . . . .	110

## CHAPTER 12

<b>Quality Criteria of Gamma Probes: Requirements and Future Developments . . . . .</b>	<b>113</b>
Introduction . . . . .	113
Quality Criteria . . . . .	113
Radial Sensitivity Distribution . . . . .	114
Spatial Resolution . . . . .	114
Sensitivity . . . . .	115
Shielding . . . . .	115
Energy Resolution . . . . .	118
Display and Acoustics . . . . .	118
Probe Shape . . . . .	118
Results . . . . .	118
Future Developments . . . . .	120
References . . . . .	125

## CHAPTER 13

<b>Statistical Evaluation in Detection of the SLN(s) . . . . .</b>	<b>127</b>
References . . . . .	128

## CHAPTER 14

<b>Are the Technical Conditions for SLN Detection Satisfactory? . . . . .</b>	<b>129</b>
Investigations of Breast Cancer Cases As a Basic Parameter . . . . .	129
Detection Rate and Accuracy of SLN Detection in Dependence on Tumor Diameter . . . . .	130
References . . . . .	130

---

CHAPTER 15  
**Breast Cancer Diagnosis Based on Histopathology and/or Cytopathology Before Sentinel Lymph Node Labeling** . . . . . 131

Reasons for Histology/Cytology-based Diagnosis of Breast Cancer Before Sentinel Lymph Node Labeling . . . . . 131

Routine and Special Histopathological and Cytopathological Techniques . . . . . 131

Basic Need for Qualified Diagnostic Methods in the Context of the “SLN Concept” . . . . . 132

MR Imaging Support of Needle Biopsy for Preoperative Detection of Multifocality and/or Multicentricity of Breast Cancer . . . . . 133

Selective Use of the Different Needle Biopsy Techniques . . . . . 133

Advantages of Using Combined Methods . . . . . 133

Suitability of These Minimally Invasive Diagnostic Methods for Confirmation or Exclusion of Breast Cancer . . . . . 136

Comparison of the Different Needle Biopsy Techniques by Proportion of Correct Diagnoses . . . . . 136

References . . . . . 138

  

CHAPTER 16  
**Success of Stereotactic Fine-Needle Aspiration Cytology Depending on Quality of Sampling** . . . . . 139

References and Further Reading . . . . . 142

  

CHAPTER 17  
**Use of a Newly Developed Ultrarapid Immunohistochemical Method to Improve Security in Sentinel Node Investigation and Timing in Interdisciplinary Cooperation** . . . . . 145

Methodical Options . . . . . 146

Technical Procedure for Ultrarapid Immunohistochemistry . . . . . 146

Preliminary Experience with Ultrarapid Immunohistochemistry Staining . . . . . 146

Differences in Application . . . . . 148

Planning for the Future . . . . . 148

References . . . . . 149

  

CHAPTER 18  
**“Micrometastasis” Versus “Microinvolvement”** . . . . . 151

Does This Discussion Hinder Decision Making? . . . . . 151

References . . . . . 153

## CHAPTER 19

<b>Preoperative Axillary Lymph Node Diagnosis Using Ultrasmall Particles of Iron Oxide Combined with MRT</b> .....	155
Evaluation of Value .....	157
Lymph Node Staging by Means of USPIO in Lung Cancer Patients ....	159
References .....	159

## CHAPTER 20

<b>New Strategies and Devices for Combined Radiological and Histological Cancer Diagnosis – Exclusion or Confirmation</b> .....	161
Commercially Available Biopsy Systems .....	162
Lorad MultiCare .....	169
Minimally Invasive Excision Biopsy Using the ABBI Device .....	169
Background to Presentation of the Various Devices .....	173
References .....	174

**Special Part****The Sentinel Node Concept Related to Main Tumor Types and Subtypes: Applicability in Daily Routine Work**

## CHAPTER 21

<b>Breast Cancer</b> .....	177
Development of the Sentinel Lymph Node Concept (Initial Approaches) .....	177
Primary- and Lymph Node-detecting Radiodiagnostic Systems Besides Mammography and Ultrasound .....	179
Role of PET in Breast Cancer Staging .....	181
Value of PET in Staging: Conclusions Derived from Positive and Negative Results in Axilla Staging .....	182
PET Screening Investigations for Sentinel Node (Axillary) and Systemic Metastasis in Breast Cancer Patients .....	182
Can the ACR-BI-RADS Lexicon Influence the Choice of the Most Adequate Device for Removal of the Breast Lesion? .....	183
Sentinel Node Localization in the Different Node Groups .....	188
Warning Signals for Our Strategy in SLN Investigation of Breast Cancer Patients .....	205
Localization of the SLNs in Multifocal and Multicentric Breast Cancer .	205
Ductal Carcinoma In Situ .....	220
Gamma Probe Handling in the Operation Room and Sterilization Procedures .....	228
References .....	250

---

CHAPTER 22	
<b>Thyroid Cancer</b> .....	257
Is the Sentinel Lymph Node Concept Practicable and Acceptable in the Diagnosis and Treatment of Thyroid Cancer? .....	257
Is FDG-PET Helpful in T- and N-staging of Thyroid Cancer? .....	257
Properties of Primaries in the Thyroid Gland and Staging by Surgeons and Histo- and Cytopathologists Working Together .....	258
References .....	281
CHAPTER 23	
<b>Cancers of the Face, Nose, Pharynx, and Oral Cavity</b> .....	283
Head and Neck: Introduction .....	283
Significance of PET in Head and Neck Tumor Staging .....	284
Cancers of the Face, Naso-pharynx and Oral Cavity and of the Salivary Glands .....	285
Dependence of Adjuvant Therapy Regimens in SCCs of the Upper Aerodigestive Tract and the Face on SLN Status .....	292
Cancer-infiltrated Cervical Lymph Nodes as Part of a Cancer with Unknown Primary .....	292
Histology and Cytology of Benign and Malignant Tumors of the Salivary Glands (Mainly of the Parotid Gland) .....	293
Special Subtypes of Ductal Salivary Gland Cancers .....	297
No Need for Discussion of SLN-Dependent Chemotherapy Strategies ..	298
References .....	298
CHAPTER 24	
<b>Lung Cancer</b> .....	301
Introduction .....	301
Initial Laboratory Investigations other than Radiodiagnosis and Histo-/Cytological Analysis to Assure Diagnosis and Subtype of Lung Cancer .....	301
Useful Serological Parameters in Confirmation of SCLC .....	301
Is N0-status Predictable in Cases with Normal CEA Values and a Tumor Shadow Disappearance Rate of 0.8 or More? .....	302
Elimination of Peripheral Noncancerous Lesions and Confirmation of Peripheral (Scar) Cancers .....	302
Primary Multicentricity of Lung Cancer: Compatibility with the SLN Concept? .....	304
Significance of PET in Staging Lung Cancer .....	305
T-staging Supported by FDG-PET .....	306
N-staging [Search for Cancer-infiltrated SLN(s)] by FDG-PET .....	306
Conclusions .....	307
Stage Values of PET-CT-MRI Pre-evaluation, Mediastinoscopy and SLN Search in N-staging of NSCLC .....	307
Exclusion of Primary Mediastinal Neoplastic Lesions in Differential Diagnosis Against Mediastinal Metastases of Primary Lung Cancers	310
N-level-dependent Survival .....	317

Skip Metastasis of NSCLC Makes N-staging More Difficult . . . . .	323
Comparative Studies of Mediastinal Lymph Node Dissection with Systematic Node Sampling . . . . .	323
Is the SLN Concept Helpful in Correct Node Staging? . . . . .	327
References . . . . .	328

## CHAPTER 25

<b>Malignant Melanoma</b> . . . . .	331
Introduction . . . . .	331
Exclusion of Nonmalignant, Nonmelanoma Lesions of the Skin . . . . .	331
Macroscopic Criteria for Malignant Melanoma Development in Pre-existing Nevi . . . . .	331
Initial Risk of Tumor Progression, Risk of Recurrence, and Definitive Risk to Survival . . . . .	332
Clinical Staging of Malignant Melanoma Based on EORTC Evaluation . . . . .	333
In Transit Metastasis, Double or Multiple Drainage, Bypass and Atypical Metastasis . . . . .	335
Interval Metastases . . . . .	336
Morphological Stages of Development of Malignant Melanoma and Different Main Subtypes . . . . .	337
Historical Overview of SLN Diagnosis for Melanomas . . . . .	339
Possible Ways of Searching for the Primary in Atypical or Nodermal Localizations . . . . .	341
Malignant Melanomas of the Anal Circle and the Rectum . . . . .	342
Immunohistochemical Support in the Diagnosis of Dysplastic Nevi and Early Invasive Malignant Melanomas . . . . .	343
Possibilities for Cytopathological Confirmation of the Diagnosis of Malignant Melanomas in Cancer-infiltrated Lymph Nodes in Cases with Primarily Undetected Primaries . . . . .	343
Exclusion of Systemic Disease in Malignant Melanoma Cases and N-staging Supported by FDG-PET . . . . .	345
Accumulating Experiences in Sentinel Node Detection in Malignant Melanomas . . . . .	347
Final Version of the Staging System for Cutaneous Melanomas . . . . .	360
References . . . . .	362

## CHAPTER 26

<b>Esophageal and Gastrointestinal Cancer</b> . . . . .	369
Current Status of International Research Activity: an Overview . . . . .	369
Esophageal Cancer . . . . .	369
N-staging Concepts Deviating from the Common Sentinel Node Concept in Esophageal Cancers . . . . .	369
Relative Value of FDG-PET – Summary . . . . .	370
Conclusions Based on the Current Status . . . . .	371
Adenocarcinoma of the Esophagogastric Junction, Including Typical “Cardia Carcinoma” . . . . .	371
Gastric Cancer . . . . .	372



Relevance of *c-erb B1-3* Oncogene Overexpression for Suggestions  
 About the Regional Lymph Node Status in Gastric Cancer Patients . . . 380  
 Colorectal Cancers . . . . . 386  
 FDG-PET in Detection and Staging of Colorectal Cancer . . . . . 387  
 Up-staging by Focused Analysis of SLNs in Cancers of the  
 Gastrointestinal Tract . . . . . 393  
 Adjuvant Therapy Regimens in CRC Depending on the Sentinel  
 and General Lymph Node(s) Status . . . . . 396  
 FDG-PET in the Diagnosis of Pancreatic Cancer . . . . . 396  
 References . . . . . 397

CHAPTER 27

**SLN Staging in Carcinoids and Neuroendocrine Tumors . . . . . 401**

Origin, Development and Definitions Pertaining to the Neuroendocrine  
 System . . . . . 401  
 Epidemiology of Carcinoids . . . . . 401  
 Level of Malignancy of Carcinoids and Other Neuroendocrine Tumors  
 (General Overview) . . . . . 403  
 Methods of Confirming the Neuroendocrine Character and the Specific  
 Subtype of these Tumors . . . . . 404  
 Is the SLN Concept Generally Applicable in the Case of Neuroendocrine  
 Tumors? . . . . . 404  
 Early Experience with <sup>111</sup>In-pentetreotide . . . . . 404  
 Clinical Significance of Blood Chromogranin . . . . . 405  
 Is PET Helpful in Preoperative N-staging of Aggressive Neuroendocrine  
 Tumors? . . . . . 405  
 Preliminary Results in FDG-PET Staging of Neuroendocrine Tumors  
 of the Gastrointestinal Tract . . . . . 406  
 Is Determination of Somatostatin Receptor Subtypes (sstr 1-5)  
 in Biopsies Helpful in Sentinel Node Search Strategies  
 and Subsequent Therapy Planning? . . . . . 406  
 Special Problems in Documentation of Early Lymphatic Spread  
 of Neuroendocrine Cancers in the Upper Abdominal Region . . . . . 407  
 Strategies to Discriminate Between Gastrointestinal, Pancreatic, and  
 Pulmonary Carcinoids in Metastatic Tissues (Lymph Nodes, Liver) . . . 407  
 Characteristics and Spectrum of Neuroendocrine (Carcinoid)  
 Tumors of the Stomach . . . . . 408  
 Characteristics and Spectrum of Neuroendocrine (Carcinoid)  
 Tumors of the Stomach . . . . . 409  
 Lymphogenic Metastasis (Rough Overview) . . . . . 409  
 Histopathology and Immunohistochemical Confirmation of Gastric  
 Carcinoids . . . . . 409  
 Detection of Stomach Carcinoids by Means of Somatostatin Receptor  
 Scintigraphy . . . . . 410  
 Clinical and Morphological Correlations of Gastric Carcinoids . . . . . 411  
 Localization and Spectrum of Carcinoids of Small Intestine and Colon  
 Carcinoids of the Colon, Especially of the Rectum, and Search  
 for Metastasis . . . . . 412  
 Lymphatic Basins and SLN Positions Corresponding to Carcinoids  
 Located in Small Intestine and Colon . . . . . 412

Influence of Hematogenous Spread on Survival . . . . .	413
Treatment Strategies in Gastrointestinal Carcinoids . . . . .	413
Endocrine Tumors of the Pancreas and Duodenum . . . . .	414
Macroscopic, Histopathological and Immunohistochemical Subtyping of Pancreatic Endocrine Tumors . . . . .	415
Spectrum of Neuroendocrine Tumors of the Lung . . . . .	415
Is Preoperative Sentinel Node Imaging Helpful in Increasing the Cure Rates in Neuroendocrine Lung Tumors? . . . . .	418
Neuroendocrine Tumors of the Retroperitoneum and the Prevertebral Thoracic and Cervical Region . . . . .	421
Peripheral Neuroendocrine Cancers Located Subepidermally or Deeper . . . . .	421
Neuroendocrine Cells in Carcinomas . . . . .	423
Search for Metastases in Neuroendocrine Tumors Before Surgical Treatment . . . . .	423
Developments in Detection of Neuroendocrine Cancers and their Metastases in SLNs using <sup>111</sup> In-labeled and <sup>123</sup> I or <sup>131</sup> I Compounds . . . . .	425
Adjuvant Therapy Regimens in the Treatment of Neuroendocrine Tumors Related to the Sentinel and General Lymph Nodes Status . . . . .	425
Targeting in Medullary Thyroid Cancer . . . . .	426
The SLN Approach in Neuroblastomas . . . . .	426
Strategies in Neuroblastoma in General and in Dependence on the Lymph Node Status . . . . .	429
References . . . . .	429

## CHAPTER 28

**The Sentinel Node Concept in Cancers of the Female Genitalia . . . . .** 431

Introduction . . . . .	431
Vulvar Cancer . . . . .	431
Acceptance of the SLN Concept in Vulvar Cancer Treatment? . . . . .	434
Cervical Cancer . . . . .	434
Problems in Local Administration of Labeling Solutions . . . . .	435
Ovarian Cancer . . . . .	435
References . . . . .	437

## CHAPTER 29

**Cancers of the Male Genitalia . . . . .** 439

Sentinel Lymph Node Identification in Penile Cancers . . . . .	439
Treatment Strategies in Premalignant and Occult Malignant Lesions . . . . .	440
Labeling the SLNs in Penile Cancers by Application of <sup>99m</sup> Tc-Nanocolloid . . . . .	440
Testicular Cancers . . . . .	442
Main Macroscopic and Microscopic Features of Malignant Testicular Tumors . . . . .	442
Biological Prognostic Factors: Implications for Risk-adjusted Therapy Regimens . . . . .	444
Initial, Meanwhile Obviously Abandoned, Approach to Retroperitoneal (Sentinel) Node Labeling in Testicular Cancer . . . . .	445

Can Radiotherapy or Chemotherapy be at Least Partly Replaced  
by More Accurate Stage-related Surgical Treatment? ..... 445

Is FDG-PET Helpful in N-staging of Germ Cell Tumors  
(SGCT and NSGCT)? ..... 446

Prospective Views ..... 447

References ..... 447

CHAPTER 30

**Prostate Cancer: an Overview** ..... 449

General Remarks ..... 449

Serum Values of Prostate-specific Antigen and Prostate Acid  
Phosphatase as Indicators for Cancer, Metastatic Spread and Cancer  
Recurrence ..... 449

Definition of the Degrees of Malignancy in Gleason's Grading  
Scoring System ..... 449

Correlations with Molecular Biological and Clinical Parameters ..... 451

Importance of Tumor Volume to Clinical Significance in Treatment  
of Prostate Cancer ..... 455

Relation Between Dysplasia and Cancer ..... 455

Gleason Score (Grading) in Ultrasound-guided Biopsies Related  
to Results in Prostatectomy Specimens ..... 456

Simultaneous Lymphogenous and Hematogenous Metastatic Spread? .. 457

Significance of Degree of Malignancy and Number of Biopsies Taken  
for N-staging and the Sentinel Lymph Node Concept ..... 458

Is the Primary Cancer Detection Rate Higher with Twelve Biopsies  
than with Six? ..... 459

Basic Research for Complete Pelvic Lymph Node (N-) Staging ..... 459

Is Laparoscopic Lymph Node Staging Equivalent to Open Pelvic  
Lymph Node Dissection? ..... 463

Intraoperative and Postoperative Lymph Node Staging in the Treatment  
of Prostate Cancer ..... 463

Is Whitmore's Staging Scheme Established in 1984 Still Compatible  
with Our Current Knowledge? ..... 464

Development of a SLN Concept in Relation to Tumor Stages ..... 466

Current Survival Rates as a Measure of Improvements in Lymph  
Node Staging and Clearance by the Sentinel Node Concept ..... 467

Does Radical Prostatectomy Improve the Results in Lymph Node-  
Positive Cases (D1)? ..... 469

In Conclusion ..... 469

Wawroschek's, Vogt's and Harzmann's First Approach to Detection  
of Sentinel Nodes in Prostate Cancer ..... 470

Experiences of the Augsburg Research Group ..... 473

Performance of the Labeling Procedure in Prostate Cancer Cases ..... 474

Detection of the SLN(s) after <sup>99m</sup>Tc-nanocolloid Labeling ..... 474

Removal of Labeled Lymph Nodes from the Paraprostatic, Iliac,  
Obturator, and Retrocolic Basins ..... 474

Is FDG-PET Helpful in Detection and N-staging of Prostate Cancer? .. 477

Can Sentinel Node Labeling be Improved According to Animal  
Experimental Studies? ..... 477

References ..... 477

## CHAPTER 31

<b>Cancers of the Urinary Tract</b> .....	481
Urinary Bladder Cancer .....	481
First Attempts at Detection and Clearance of Sentinel Nodes before Cystectomy .....	482
Conclusion .....	482
Staging by Means of Positron Emission Tomography in Urinary Bladder Cancer .....	483
Renal Cell Cancer .....	483
Staging before Surgical Treatment .....	484
Lymph Drainage of RCC Differs with Laterality .....	485
Cytology of RCC .....	487
Lymph Node Staging in RCC .....	487
“Checklist” of Possible Methods of Lymph Node Investigation .....	489
Do Immunohistochemically Detectable Prognostic Factors have Significance for Treatment Strategies Including the Search for Sentinel Lymph Nodes? .....	490
Detection of SLNs by Cancer-specific Immune Response? .....	491
Is there a Benefit of Extensive Lymphadenectomy over Sampled Lymphadenectomy? .....	491
Is Retroperitoneal Lymphadenectomy Helpful in Extending Survival in Patients with Hematogenous Metastases from RCC? .....	491
Adrenal-sparing Surgery in Cases with RCC .....	492
Proposal for Sentinel Node Labeling in RCCs .....	492
Can FDG-PET Help in N-staging of RCC and Bladder Cancer? .....	493
Laparoscopic Retroperitoneal Partial and Radical Nephrectomy in RCCs .....	494
Use of Microwaves as a Styptic in Partial Nephrectomy .....	494
Adjuvant Therapy Regimens in Cases with Metastatic RCC .....	494
References .....	495

## CHAPTER 32

<b>Closing Remarks</b> .....	499
Technical News .....	501
References .....	502

## CHAPTER 33

<b>Therapy Regimens Used in Adjuvant and Neoadjuvant Treatment of the Discussed Tumor Types</b> .....	503
Adjuvant Chemotherapy Regimens for Breast Cancer .....	504
Therapy Regimens for Thyroid Cancer .....	509
Therapy Regimens for Head and Neck Cancers .....	510
Chemotherapy Regimens for Lung Cancer .....	513
Therapy Regimens for Esophageal Cancer .....	517
Chemotherapy Regimens for Gastric Cancer .....	518

---

Therapy Regimens for Colorectal Cancers . . . . .	520
Therapy Regimens for Neuroendocrine Tumors . . . . .	522
Therapy Regimens for Neuroblastoma . . . . .	525
Therapy Regimens for Malignant Melanoma . . . . .	529
Therapy Regimens for Soft Tissue Tumors . . . . .	530
Therapy Regimens for Renal Cell Cancer . . . . .	531
Therapy Regimens for Prostate Cancer . . . . .	533
Therapy Regimens for Vulvar Cancer . . . . .	535
Therapy Regimens for Cervical Cancer . . . . .	536
Therapy Regimens for Urinary Bladder Cancer . . . . .	538
Adjuvant Therapy for Prevention of Severe Neutropenia, Possibly followed by Infections . . . . .	541
New Approaches to Halting Cancer Cell Spread by Immunological Blockade of Neoangiogenesis . . . . .	541
References and Recommended Further Reading . . . . .	542
<b>Subject Index . . . . .</b>	<b>553</b>